There are currently no molecular targeted approaches to treat SCLC similar to those used successfully against non-small-cell lung cancer (NSCLC), such as erlotinib targeting of mutant EGFR or crizotinib targeting of EML4-ALK fusion proteins [6], [7]. Here, ALK is linked to non-small cell lung carcinoma.